Oncolytics Biotech Shows Promising Colorectal Cancer Data Driving ONCY Stock Up
Oncolytics Biotech announced a 19.5-month median response duration for pelareorep in colorectal cancer, significantly outperforming historical benchmarks. This data, alongside a potential accelerated approval pathway with the FDA, has positively influenced investor sentiment, leading to a notable rise in ONCY's stock price.
View signal analysis